Details on upcoming events are not yet available. Please click here to be notified of all upcoming events.
ASH 2017 PresentationsSafety and preliminary clinical activity of REGN1979, an anti-CD20 × anti-CD3 bispecific antibody, in patients with B-NHL previously treated with CD20-directed antibody therapy378.6 KBSafety and Preliminary Antitumor Activity of the Anti-PD-1 Monoclonal Antibody Cemiplimab (REGN2810) Alone or in Combination with REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with B-Lymphoid Malignancies379.3 KB
Nov 284:00 PM ET
29th Annual Piper Jaffray Healthcare ConferenceListen to webcast
Regeneron Corporate Presentation November 2017View Presentation1.3 MB